Swiss biopharmaceutical company AC Immune announced that its partner radiopharmaceutical firm Life Molecular Imaging (LMI, formerly Piramal Imaging) presented new clinical study results for F-18 PI-2620, a novel tau PET-tracer, at the recent Clinical Trials on Alzheimer's Disease Conference in Barcelona, Spain.
Intracellular tau deposition is a key pathologic feature of Alzheimer's disease and other neurodegenerative disorders. The results of the test-retest study for F-18 PI-2620 in Alzheimer's disease and nondemented controls demonstrated favorable kinetics, high target specificity with low off-target binding, and high signal in regions of expected tau pathology.
The low test-retest variability will allow for precise quantification of F-18 PI-2620 uptake in target brain areas to detect subtle changes of tau deposition over time and during therapeutic interventions in longitudinal studies, the firms said.
